DNTH241220P35000
- 0.00
- 0.000.00%
Dianthus Therapeutics Newsroom
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics
TD Cowen Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating
TD Cowen Initiates Coverage on Dianthus Therapeutics With Buy Rating
Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $52
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Oppenheimer Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $52
Dianthus Therapeutics Price Target Raised to $52.00/Share From $48.00 by Oppenheimer
Dianthus Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Raymond James Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $56
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $45
Buy Recommendation for Dianthus Therapeutics: Strong Financial Position and Promising Drug Pipeline
Express News | Dianthus Therapeutics Q3 2024 GAAP EPS $(0.74) Misses $(0.58) Estimate, Sales $2.17M Beat $648.50K Estimate
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn Into More Strength?
Baird Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $58
Guggenheim Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating